Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
7.16
Dollar change
-0.22
Percentage change
-2.98
%
Index- P/E- EPS (ttm)-8.26 Insider Own28.07% Shs Outstand0.75M Perf Week3.92%
Market Cap5.37M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.54M Perf Month-7.97%
Income-6.17M PEG- EPS next Q- Inst Own6.68% Short Float2.23% Perf Quarter38.76%
Sales0.31M P/S17.32 EPS this Y- Inst Trans- Short Ratio0.94 Perf Half Y-25.90%
Book/sh10.83 P/B0.66 EPS next Y- ROA-75.76% Short Interest0.01M Perf Year-52.27%
Cash/sh10.81 P/C0.66 EPS next 5Y- ROE-105.55% 52W Range5.00 - 16.90 Perf YTD-13.21%
Dividend Est.- P/FCF- EPS past 5Y64.02% ROI-75.81% 52W High-57.64% Beta1.34
Dividend TTM- Quick Ratio5.30 Sales past 5Y-26.72% Gross Margin49.67% 52W Low43.20% ATR (14)0.81
Dividend Ex-Date- Current Ratio5.30 EPS Y/Y TTM51.64% Oper. Margin-2600.33% RSI (14)49.30 Volatility11.89% 8.60%
Employees4 Debt/Eq0.07 Sales Y/Y TTM-46.50% Profit Margin-2014.71% Recom1.00 Target Price140.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q87.52% Payout- Rel Volume0.80 Prev Close7.38
Sales Surprise- EPS Surprise- Sales Q/Q-95.79% Earnings- Avg Volume12.83K Price7.16
SMA20-4.34% SMA504.04% SMA200-19.93% Trades Volume10,225 Change-2.98%
Date Action Analyst Rating Change Price Target Change
Jun-26-19Initiated Maxim Group Buy $4
Nov-10-17Downgrade ROTH Capital Buy → Neutral
Jan-25-24 04:29PM
Dec-28-23 04:15PM
Nov-14-23 07:23PM
Oct-16-23 04:37PM
Sep-18-23 07:30AM
12:44PM Loading…
Aug-28-23 12:44PM
Aug-15-23 08:46AM
Jul-27-23 07:30AM
Jan-27-23 07:00AM
Dec-15-22 07:00AM
Dec-12-22 07:49AM
Nov-17-22 05:35AM
Aug-16-22 10:53AM
Jul-11-22 08:00AM
Jul-09-22 09:07AM
08:00AM Loading…
Jul-05-22 08:00AM
Jun-10-22 08:00AM
Apr-25-22 01:29PM
Feb-02-22 12:27PM
08:45AM
Dec-21-21 08:00AM
Nov-08-21 04:15PM
Nov-05-21 04:30PM
Oct-25-21 07:15AM
Oct-12-21 08:00AM
Aug-20-21 02:52PM
Aug-04-21 09:34AM
Jun-23-21 08:00AM
Mar-31-21 04:30PM
Feb-01-21 07:30AM
09:15AM Loading…
Jan-15-21 09:15AM
Dec-16-20 08:00AM
Dec-01-20 04:56AM
Nov-30-20 12:50PM
Nov-16-20 08:45AM
Nov-02-20 08:00AM
Oct-30-20 08:14AM
Oct-28-20 03:00PM
08:00AM
Oct-26-20 06:30AM
Oct-15-20 08:00AM
Sep-24-20 09:00AM
Sep-18-20 04:45PM
Sep-16-20 01:05PM
Sep-15-20 08:30AM
Sep-14-20 08:30AM
Aug-26-20 05:45AM
Aug-14-20 08:45AM
Aug-10-20 04:30PM
Jul-08-20 08:00AM
Jun-24-20 08:00AM
Jun-16-20 08:00AM
Jun-01-20 05:20AM
May-15-20 08:45AM
May-11-20 04:03PM
Apr-09-20 06:15AM
Apr-02-20 09:47PM
Mar-31-20 12:43PM
Mar-30-20 04:03PM
02:30PM
Mar-26-20 08:00AM
Mar-05-20 09:00AM
Feb-18-20 08:55AM
Jan-13-20 08:00AM
Jan-07-20 09:15AM
Dec-30-19 08:00AM
Dec-17-19 10:30AM
Dec-04-19 01:22PM
Dec-03-19 09:00AM
Nov-25-19 05:15AM
Nov-14-19 04:03PM
Nov-07-19 04:30PM
Oct-22-19 08:00AM
Oct-18-19 10:23AM
Oct-16-19 09:20AM
Oct-01-19 08:00AM
Sep-18-19 08:00AM
Aug-30-19 08:01PM
Aug-23-19 11:30AM
Aug-17-19 09:59AM
Aug-16-19 07:33AM
Aug-14-19 04:03PM
07:32AM
Aug-09-19 05:00PM
Aug-07-19 09:15AM
Jul-09-19 09:00AM
Jul-03-19 10:54AM
Jun-26-19 09:10AM
Jun-04-19 07:00AM
May-29-19 02:15PM
May-23-19 08:10AM
May-15-19 04:08PM
04:03PM
May-13-19 07:00AM
May-08-19 08:00PM
May-06-19 03:12PM
Apr-29-19 07:00AM
Apr-12-19 05:00PM
Apr-11-19 09:45AM
Apr-02-19 01:06AM
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lazar David E.Chief Executive OfficerJun 21 '23Sale1.233,388,9024,168,3490Jun 23 04:07 PM
Lazar David E.Chief Executive OfficerJun 21 '23Sale1.23359,066441,6510Jun 23 04:07 PM